Atlas One · Host Biology · Scale 07 — System

HNSCC

Head and neck SCC; HPV+ oropharyngeal HNSCC (TP53 WT, PI3K-active) has better prognosis than HPV-negative (TP53 ~80%, CDKN2A ~40%); cetuximab and pembrolizumab are approved; KEYNOTE-048 defines first-line pembrolizumab over EXTREME in PD-L1+ recurrent/metastatic disease.

Also known as: HNSCC, head and neck squamous cell carcinoma, oral cavity cancer, oropharyngeal cancer, HPV-positive HNSCC, laryngeal cancer, hypopharyngeal cancer, head and neck cancer

Scale 07 — SystemScale
draftStatus
2026-06-06Last Reviewed
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
hnscc

HNSCC

Head and neck SCC; HPV+ oropharyngeal HNSCC (TP53 WT, PI3K-active) has better prognosis than HPV-negative (TP53 ~80%, CDKN2A ~40%); cetuximab and pembrolizumab are approved; KEYNOTE-048 defines first-line pembrolizumab over EXTREME in PD-L1+ recurrent/metastatic disease.

Entry Metadata

FieldValue
IDhnscc
NameHNSCC
Statusdraft
Last reviewed2026-06-06
Atlas01-human
Scale07-system

Cross-Atlas Connections

connects-toEgfr connects-toPd 1 connects-toP53 connects-toPik3Ca connects-toEpstein Barr Virus connects-toRb1 connects-toCdkn2A connects-toEsophageal Cancer connects-toCervical Cancer connects-toT Cytotoxic Cell connects-toAlcohol Use Disorder connects-toCarbon connects-toHpv 16

Sources